Samuel Arnold

Dr. Samuel Arnold is an Assistant Professor in the Department of Pharmaceutics at the University of Washington School of Pharmacy, where he joined in 2023. His research focuses on characterizing exposure-response relationships for therapeutic treatment of infectious diarrhea, particularly for pathogens like Cryptosporidium and Shigella. As a member of the Bill & Melinda Gates Foundation Cryptosporidium Drug Accelerator (CryptoDA), Dr. Arnold has led significant efforts to identify pharmacokinetic/pharmacodynamic relationships for anti-cryptosporidiosis drugs.

Dr. Arnold earned his Bachelor of Science in Biochemistry from the University of Colorado and his Ph.D. in Pharmaceutics from the University of Washington. His research interests center on infectious diseases, particularly pharmacokinetic-pharmacodynamic modeling for treatment of enteric infections, enteric disease induced changes in drug disposition, and improved preclinical models of drug disposition in the gastrointestinal tract. His expertise spans drug discovery, in vitro to in vivo extrapolation, intestinal surgery and GI diseases, microphysiological organ systems, pharmacokinetics-pharmacodynamics, pharmacology, simulation modeling, and translational research.

Dr. Arnold's publication record demonstrates significant contributions to the understanding of diarrheal diseases and their impact on drug pharmacokinetics. His work shows a clear progression from foundational studies on parasitic infections to clinical applications, with a strong emphasis on translational research that bridges laboratory findings with clinical practice. Recent publications highlight his focus on physiologically based pharmacokinetic modeling to predict how diarrheal diseases affect oral drug pharmacokinetics, as well as ongoing clinical investigations into novel treatments for shigellosis and cryptosporidiosis.

Dr. Arnold actively participates in collaborative research initiatives, including clinical trials investigating clofazimine as a potential anti-cryptosporidiosis treatment (Clinicaltrials.gov #NCT03341767). His lab is working on developing pharmacokinetic models that can predict the impact of diarrhea on drug exposure prior to human dosing, which represents a significant advancement in the field of infectious disease pharmacology.

Dr. Arnold accepts students to his laboratory and teaches courses PCEUT531, PCEUT532, and PCEUT506 at the University of Washington School of Pharmacy. His research has important implications for global health, as diarrheal diseases remain the second leading cause of death in children under five years old worldwide.